|
市場調查報告書
美國呼吸器官疾病市場
SPECIAL REPORT: How Will the Withdrawal of Generic Albuterol Change the U.S. Respiratory Disease Market?
|
本報告已在2011年12月21日停止出版。
專門於醫療產業相關廣泛調查的美國市調公司Decision Resources Inc.(總公司：Massachusetts State) 針對美國呼吸器官疾病市場進行調查分析，並出版經系統整理的報告書"SPECIAL REPORT: How Will the Withdrawal of Generic Albuterol Change the U.S. Respiratory Disease Market?"。
本報告書內容包括：呼吸器官疾病市場概要及蒙特婁協定、從CFC到HFA的需求變化、未來市場發展預測等。內容綱要摘記如下：
實施概要
介紹
蒙特婁協定
呼吸器官疾病
- 氣喘簡介
- 慢性阻塞性肺病（COPD）簡介
- 氣喘及COPD治療時支氣管擴張劑之利用
呼吸器官疾病市場
朝HFA發展時的課題
市場發展前景
- Albuterol的需求
- 競爭威脅
- 美國市場預測
- 贏家及輸家
附錄A：美國2006年至2011年的品牌HFA產品市場預測情境
- 方法論及假設
- 情境1：Proventil HFA領導市場
- 情境2：競爭價格
- 情境3：醫生選擇Xopenex
表
- 氣喘及COPD的罹患案例：2006年
- 氣喘及COPD治療用主要藥物銷售金額：2006年
- 美國的鬆弛劑銷售預測：2008年至2011年
- 美國2006年至2011年的氣喘及COPD治療人口
- 針對單一患者的HFA劑年度成本
圖
- Albuterol的銷售金額：1986年至2006年
- 美國的Albuterol銷售金額：2000年至2006年
Abstract
Introduction:
The albuterol inhaler market in the United States will soon change from
low-value to significant. The only MDIs sold will be branded HFA formulations;
CFC propellants will be eliminated. Because the new HFA formulations are not
bioequivalent, companies will compete for market leadership by convincing
physicians and patients of their product' s superiority and by making strategic
pricing decisions.
Questions Answered in This Spectrum Report:
- The imminent discontinuation of many generic formulations of albuterol in
the United States will be the most signifi cant change in the respiratory
disease market in some time. Will today' s sales leaders weather the change
and continue to enjoy market dominance? How will the change affect generics
manufacturers? What marketing strategies will be key elements in development
of the market between 2006 and 2011? What are the market leaders doing now?
- As production of albuterol CFC ends, patients will have to switch from
familiar generics to more-expensive, branded HFA formulations that are not
interchangeable despite having the same active ingredient. How can
companies differentiate their products to win patient and physician
allegiance? How will higher costs affect patients and reimbursement providers?
How will they react?
- By the beginning of 2009, the U.S. market for inhaled albuterol MDIs will
comprise branded products exclusively. Which products will drive the market
at least until 2011? Which company is likely to own the biggest market share
in 2011? Which companies will lose market share? Are new companies with new
formulations likely to impact the market by 2011?
Scope
- Respiratory disease market: asthma and chronic obstructive
pulmonary disease prevalence and treatment; albuterol agents and manufacturers.
- Montreal Protocol: ban on CFC propellants; impact on the albuterol
market and on brand and generic manufacturers, consumers, and payers.
- From CFC to HFA: supply and demand challenges; manufacturer
compliance; non-bioequivalence of HFAs; reimbursement issues.
- Market outlook: continuing demand for albuterol products; DPI
formulations; pricing and product differentiation; U.S. market forecast;
winners and losers.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- The Montreal Protocol
- Respiratory Diseases
- An Overview of Asthma
- Disease Defi nition, Etiology, and Prevalence
- Treatment of Asthma
- An Overview of Chronic Obstructive Pulmonary Disease
- Disease Defi nition, Etiology, and Prevalence
- Treatment of COPD
- Use of Symptomatic Bronchodilators in the Treatment of Asthma and COPD
- The Respiratory Disease Market
- Controller Agents
- Reliever Agents
- The Albuterol Market in the United States
- Challenges of the Switch to HFA Formulations
- Demand and Manufacturing Concerns
- Manufacturer Compliance
- Lack of Equivalence
- Reimbursement Issues
- Market Outlook
- Demand for Albuterol
- Competitive Threats
- U.S. Market Forecast
- Winners and Losers
- Appendix A. Market Forecast Scenarios for Branded HFA Products in the
United States, 2006-2011
- Methodology and Assumptions
- Drug-Treated Population
- Treated Days and Compliance
- Price per Patient per Year
- Scenario 1: Proventil HFA Takes Early Market Leadership
- Scenario 2: Competitive Pricing
- Scenario 3: Physicians Choose to Switch Patients to Xopenex
Tables
- 1. Prevalent Cases of Asthma and COPD, 2006
- 2. Sales of Leading Agents to Treat Asthma and COPD, 2006
- 3. Forecasted Sales of Reliever Agents in the United States, 2008 and 2011
- A. Combined Asthma and COPD Drug-Treated Populations in the United States,
2006-2011
- B. Annual Cost of HFA Agents for a Single Patient
Figures
- 1. Sales of Albuterol, 1986 - 2006
- 2. Sales of Albuterol in the United States, 2000-2006
- A. Sales of Short-Acting Beta2 Agonists (Scenario 1: Proventil Takes Early
Market Leadership), 2006-2011
- B. U.S. Market Shares, 2011 (Scenario 1: Proventil Takes Early Market
Leadership)
- C. Sales of Short-Acting Beta2 Agonists (Scenario 2: Competitive Pricing),
2006-2011
- D. U.S. Market Shares, 2011 (Scenario 2: Competitive Pricing)
- E. Sales of Short-Acting Beta2 Agonists (Scenario 3: Physicians Switch
Patients to Xopenex), 2006-2011
- F. U.S. Market Shares, 2011 (Scenario 3: Physicians Switch Patients to
Xopenex)
Sidebars
- Barriers to Entry:What Is Discouraging Companies from Developing Albuterol?
- How Will Albuterol Manufacturers Differentiate Their Products?
|
